Novel compound heterozygous \textit{STN1} variants are associated with Coats Plus syndrome

Tanvi Acharya\textsuperscript{1} | Helen V. Firth\textsuperscript{2} | Shilpa Dugar\textsuperscript{3} | Tassos Grammatikopoulos\textsuperscript{3} | Luis Seabra\textsuperscript{4} | Angharad Walters\textsuperscript{5} | Yanick J. Crow\textsuperscript{6} | Alasdair P. J. Parker\textsuperscript{7}

\textsuperscript{1}School of Clinical Medicine, Cambridge University, Cambridge, UK
\textsuperscript{2}Department of Clinical Genetics, Addenbrooke’s Hospital, Cambridge, UK
\textsuperscript{3}Paediatric Liver, GI and Nutrition Centre and Mowat Labs, King’s College Hospital NHS Foundation Trust, London, UK
\textsuperscript{4}Laboratory of Neurogenetics and Neuroinflammation, Institut Imagine, Paris, France
\textsuperscript{5}Cambridgeshire Community Services, Brooksfield Hospital, Cambridge, UK
\textsuperscript{6}Centre for Genomic and Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
\textsuperscript{7}Department of Paediatric Neuroscience, Addenbrooke’s Hospital, Cambridge, UK

Abstract

\textbf{Aim:} Coats plus syndrome (CP) is a rare autosomal recessive disorder, characterised by retinal telangiectasia exudates (Coats disease), leukodystrophy, distinctive intracranial calcification and cysts, as well as extra-neurological features including abnormal vasculature of the gastrointestinal tract, portal hypertension and osteopenia with a tendency to fractures. CP most frequently occurs due to loss-of-function mutations in \textit{CTC1}. The encoded protein CTC1 constitutes part of the CST (CTC1-STN1-TEN1) complex, and three patients have been described with CP due to biallelic mutations in \textit{STN1}. Together with the identification of homozygosity for a specific loss-of-function mutation in \textit{POT1} in a sibling pair, these observations highlight a defect in the maintenance of telomere integrity as the cause of CP, although the precise mechanism leading to the micro-vasculopathy seen at a pathological level remains unclear. Here, we present the investigation of a fourth child who presented to us with retinal exudates, intracranial calcifications and developmental delay, in keeping with a diagnosis of CP, and later went on to develop pancytopenia and gastrointestinal bleeding. Genome sequencing revealed compound heterozygous variants in \textit{STN1} as the likely genetic cause of CP in this present case.

\textbf{Methods:} We assessed the phenotype to be CP and undertook targeted sequencing.

\textbf{Results:} Whilst sequencing of \textit{CTC1} and \textit{POT1} was normal, we identified novel compound heterozygous variants in \textit{STN1} (previous gene symbol \textit{OBFC1}): one loss-of-function—c.894dup (p.(Asp299Argfs*58)); and one missense—c.707T>C (p.(Leu236Pro)).

\textbf{Conclusion:} Given the clinical phenotype and identified variants we suggest that this is only the fourth patient reported to date with CP due to mutations in \textit{STN1}.

\textbf{KEYWORDS}
coats plus, leukodystrophy, stn1
1 | INTRODUCTION

Coats plus (CP) is a pleiotropic disorder affecting the brain, bone and gastrointestinal tract, with retinal telangiectasia and exudates (Coats disease), a neuroradiological triad of cerebral white matter disease (leukoencephalopathy), intracranial calcifications and cysts (LCC) and extra-neurological manifestations such as osteopenia, life-limiting gastro-intestinal bleeding and portal hypertension caused by the development of vascular ectasias in the stomach/small intestine and liver fibrosis (Crow et al., 2004; Kapuria et al., 2019; Tolmie et al., 1988).

CP has an overlapping phenotype with LCC (also known as Labrune syndrome) which is indistinguishable from CP in terms of the associated neuroradiology, but does not include the extra-neurological manifestations of CP (Labrune et al., 1996). Of note, LCC is an apparently genetically homogeneous disorder due to mutations in SNORD118 (Jenkinson, 1996). Some patients with CP display hair and bone marrow failure—resembling the phenotype of other telomopathies, including dyskeratosis congenita, Hoyeraal–Hreidarsson syndrome and Revesz syndrome (Keller et al., 2016). Some patients with CP display hair and bone marrow failure—resembling the phenotype of other telomopathies, including dyskeratosis congenita, Hoyeraal–Hreidarsson syndrome and Revesz syndrome (Keller et al., 2016).

CP has been associated with mutations in any of CTC1 (Anderson et al., 2012; Polvi et al., 2012), POT1 (Takash et al., 2016) and, in three cases, STN1 (Simon et al., 2016; Passi et al., 2020). The identification of biallelic mutations in CTC1 in individuals with CP has focussed attention on the CST (CTC1- STN1-TEN1) complex as a cause of human disease. This conserved trimeric complex has three recognised functions; binding the telomeric G-strand, promoting synthesis of the C-strand and inhibiting telomerase-mediated telomere elongation. It is thought that disruption of the CST complex affects telomere length and telomeric C-strand synthesis, leading to elongated 3’ overhangs (Stewart et al., 2012). This means that the role of telomeres as nucleoprotein complexes in the protection of chromosome ends from degradation, activation of the DNA damage response and end-to-end fusion are compromised. The principal role of STN1 is to interact and stimulate the activity of DNA polymerase a-primase, the only enzyme known to initiate DNA replication in eukaryotic cells (Stewart et al., 2012). Functional studies have shown that stable knockdown of STN1 increases the incidence of anaphase bridges and multi-telomeric signals, indicating genomic and telomeric instability (Goulian et al., 1990).

2 | CASE STUDY

The proband was a 9-year-old Caucasian male. Concerns first arose due to intrauterine growth restriction on a 20-week scan and at 27 weeks gestation his mother underwent an emergency Caesarean section because of oligohydramnios. He was born weighing 600 g, required ventilation for 2 weeks and remained hospitalised for 3 months thereafter, during which time he was naso-gastrically and subsequently percutaneous endoscopic gastrostomy (PEG) fed. At the age of 30 weeks he was considered to have features of stage 3 retinopathy of prematurity, which was treated with laser therapy in both eyes. He developed conjugated hyperbilirubinemia, attributed to his prematurity, which cleared after a few weeks. Abdominal ultrasound showed mild hepatomegaly.

His developmental milestones were at the upper end of the normal range, lifting his head at age 3 months and walking with support at 15 months of age after his expected delivery date. He had delayed speech acquisition. Cranial MRI at the age of 3 years revealed asymmetric white matter disease particularly involving the right occipital and parietal lobes, with signal change/swelling in the pons and dense calcifications (Figure 1). These features were in keeping with the radiological triad of both CP and LCC. Other considerations, such as infection and metabolic causes for the patient’s symptoms, were excluded.

His height and weight followed the 0.4th centile, with a head circumference 3.5SD below the mean. At age of 5 years he suffered a vitreous haemorrhage in the left eye requiring vitrectomy. At 6 years of age abdominal ultrasound revealed hepatosplenomegaly with elevated transaminases and no cholestasis. Liver histology showed intact lobular architecture without fibrosis, but small portal tracts lacking biliary structures. Full blood count revealed chronic thrombocytopenia and pancytopenia, with a white blood cell count of 2.1 thousands/μL, red blood cell count of 2.7 thousands/μL, haemoglobin of 9.7 g/dL and platelet count of 35 × 10^9/L. Furthermore, bone marrow aspirate and trephine revealed hypocellularity, with a reduction in the myeloid lineage.

By this time his neurological status had deteriorated, subsequently affecting his speech and with emerging dystonic posturing of the right leg / arm. Cerebral MRI scan showed progression of areas of focal intensity including the left parietal and occipital lobes, along with volume loss of the thalami and brainstem (Figure 1). He experienced episodes of haematemesis. Aged 8 years, esophago-gastro-duodenoscopy revealed grade 2–3 esophageal varices requiring esophageal band ligation (EBL). He was enrolled onto a secondary prophylaxis programme for his portal hypertension (PHT). Proctoscopy was normal. No telangiectasia-like lesions were identified in the examined GI track. His liver ultrasound and Fibroscan showed evolution of liver disease, with features of liver fibrosis and hypersplenism. The esophageal varices responded to EBL. Suspected low volume non-variceal GI bleeding was managed with tranexamic acid.
Unfortunately, his haemoglobin continued to drop to 8.8 g/dL and liver ultrasound showed marked increase in ascites with an increase in splenomegaly from 13.8 cm to 22.0 cm. Following a large rectal bleed and intolerance of feeds, he was managed palliatively, and died peacefully at age 9. Liver failure and gastrointestinal bleeding were cited as the main cause of death (Table 1).

3 | GENETIC EVALUATION

Given the CP phenotype, Sanger sequencing of CTC1 was undertaken, but no pathological variants were identified. POT1 and SNORD118 were also examined and sequences found to be wild type. In contrast, sequencing of STN1 (previous gene symbol OBFC1) identified two
rare variants; c.707T>C, p.(Leu236Pro) and c.894dup, p.(Asp299Argfs*58) in exons 7 and 9, respectively (Figure 2) —DECIPHER reference number 283482 (Firth et al., 2009; Figure 3 and 4).

Parental testing confirmed that the variants were biallelic. Of note, the p.(Leu236Pro) is not recorded in more than 250,000 control alleles on gnomAD, whilst the p.(Asp299Argfs*58) has been observed only once in 251,430

**FIGURE 2** Sanger sequencing. c.707T>C variant with amino acid substitution and c.894dup variant with sequence change downstream

**FIGURE 3** Schematic diagram of variants on STN1 protein domain

**STN1: Q9H668** 368aa (protein shown matches variant transcript)
alleles on the same control database. The c.894dup variant is predicted to create a shift in the reading frame, ending in a premature stop codon 58 positions downstream. The c.707T>C variant alters an amino acid within the C-terminal CST complex STN1 domain and is predicted as damaging by SIFT and Polyphen2.

All genetic investigations were undertaken with consent, and with appropriate ethic permissions (Leeds-west Multicentre Research Ethics Committee: REC reference: 10/ H1307/2; IRAS project ID: 62971).

4 | DISCUSSION

This boy had a long period prior to accurate molecular diagnosis, during which he developed severe multisystem disease. Coats Plus is a rare, severe, autosomal recessive disorder characterised by a relatively stereotyped set of features: leukodystrophy, calcifications and cysts; retinal telangiectasia/exudates (i.e. Coats disease); and evolving gastrointestinal involvement including hepatic fibrosis, oesophageal varices and hepatosplenomegaly. Bone marrow failure can be present in some cases. GI telangiectasis and osteopenia, two of the key features of CP, were not present in this child, re-emphasising the variability in presentations with mutations in CST components. The major cause of CP is mutations in CTC1, with a single family so-far reported harbouring a mutation in POT1. Sequencing of both of these genes was normal in our patient. Despite this, the clinical picture made any diagnosis other than CP highly unlikely. The diagnosis of CP was effectively confirmed with the identification of biallelic rare variants in STN1. The only other STN1-CP cases reported to date are two unrelated patients, each born to consanguineous Palestinian parents, found to harbour homozygous STN1 variants; c.404G>C; p.(Arg135Thr), and c.469G>T; p.(Asp157Tyr), in exons 5 and 6 of STN1, respectively (Simon et al., 2016); and an Indian child with c.397C>T (p.Arg133*) and c.985G>C (p.Ala329Pro) in exons 5 and 10, respectively (Passi et al., 2020). Further biological analysis such as telomere length by flow-FISH would be important in supporting our claim.

In summary, we report novel compound heterozygous STN1 variants associated with Coats Plus, thereby expanding the associated molecular spectrum and emphasising the devastating nature of this multi-system disease.

ACKNOWLEDGEMENTS

YJC acknowledges a state subsidy managed by the National Research Agency (France) under the ‘Investments for the Future’ programme bearing the reference ANR-10-IAHU-01. This study makes use of data generated by the DECIPHER community. A full list of centres who contributed to the generation of the data is available from http://deciphergenomics.org/about/stats and via email from contact@deciphergenomics.org. Funding for the DECIPHER project was provided by Wellcome.
CONFLICT OF INTEREST
The authors have declared no conflict of interest.

AUTHOR CONTRIBUTION
Helen V Firth, Luis Seabra and Yanick Crow conceived and planned the experiments, carried out Sanger Sequencing, analysed data and designed the figures. Alasdair PJ Parker, Shilpa Dugar, Tassos Grammatikopoulos and Angharad Walters were involved in the care of the patient, and provided the clinical details pertaining the patient. Tanvi Acharya took lead in writing the manuscript, with input from all authors.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Tanvi Acharya https://orcid.org/0000-0003-0330-6585

REFERENCES


How to cite this article: Acharya T, Firth HV, Dugar S, et al. Novel compound heterozygous STN1 variants are associated with Coats Plus syndrome. Mol Genet Genomic Med. 2021;0:e1708. https://doi.org/10.1002/mgg3.1708